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Abstract
Aims: Cardiomyopathy (CMP) with a reduced ejection fraction 
develops in a dose-dependent manner in one-third of subjects with a 
long-term history of heavy daily alcohol consumption. Ethanol alters 
heart transduction signals including excitation-contraction sarcomeric 
coupling, causing diastolic and systolic left-ventricular (LV) dysfunction. 
Titin is a giant structural sarcomeric filament macro protein involved 
in contractile heart function and contributes to cardiac myocyte elastic 
recoil, a key factor for diastolic LV filling.
We evaluated whether titin expression is affected by chronic high-
dose ethanol consumption in alcoholic CMP.
Methods and Results: We analyzed a total of 30 heart samples 
from human organ donors: 20 from high alcohol consumers (10 without 
CMP and 10 with CMP) and 10 healthy controls. Patient evaluation 
comprised daily and lifetime ethanol consumption, chest X ray, 2-D 
echocardiography and LV histology. CMP was assessed by functional 
and histological criteria. Titin activity was evaluated by specific 
immunohistochemical (IHC) and transcript expression (rtPCR) assays.
Titin IHC expression was clearly present in sarcomere areas 
of myocytes. Compared to healthy donors (82.58 ± 3.36), alcohol 
consumers showed a significantly lower cardiac titin expression (71.29 
± 3.16; 13.67 ± 3.83% decrease; p=0.04), being significantly lower in 
alcohol consumers with CMP (62.31 ± 4.18; 24.54 ± 5.06% decrease, 
p<0.0009), compared to both their counter-parts without CMP (80.27 
± 2.62; 2.80 ± 3.17% decrease vs. controls; p<0.0030 vs. alcoholic CMP). 
Titin transcript levels confirmed similar patterns of expression.
Conclusions: Cardiac sarcomeric titin expression is diminished by 
chronic alcohol consumption, especially when CMP has been developed. 
Titin is involved in the multifactorial pathogenic process of alcoholic 
CMP.
Keywords: Alcohol, Pregranulin, Myocardium, Titin expression, 
Cardiomyopathy.
Introduction 
Alcoholic cardiomyopathy (CMP) is characterized by a dilated 
left-ventricle (LV) phenotype in subjects with high-dose persistent 
alcohol consumption [1-3] which is similar to genetically-linked 
cardiomyopathies. Twenty-three to 47 % of all dilated CMPs in developed 









1Department of Internal Medicine, Hospital Clinic, Institut d’Investigacions 
Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
2Departmkent of Internal Medicine, Muscle Research and Mitochondrial 
Function Laboratory, CELLEX-IDIBAPS, Faculty of Medicine and Health 
Sciences-University of Barcelona, Spain and CIBERER
3Department of Biochemistry and Molecular Biomedicine, University of 




Received Date: 10 October, 2018
Accepted Date: 18 October, 2018
Published Date: 23 October, 2018
*Corresponding Author: Dr. Fernández-Solà Joaquim, 
Department of Internal Medicine, Hospital Clinic, Institut 
d’Investigacions Pi i Sunyer (IDIBAPS), University of 
Barcelona, Villarroel 170, 08036, Spain, Fax: 00-34-93-2275400, 
Tel: 00-34-93-2275400, Email: jfernand(at)clinic.cat
Citation: Fernández-Sola J, Toll-Argudo M, Tobías-Baraja 
E, Moreno- Lozano P, Ferrer-Curriu G, Guitart-Mampel M, 
Planavila-Porta A, Garrabou-Tornos A (2018) Decreased 
Myocardial Titin Expression in Chronic Alcoholic 
Cardiomyopathy. J Cardiovas Disea Medic Vol: 1, Issu: 1 
(63-70).
Copyright: © 2018 Fernández-Solà J. This is an open-
access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided 
the original author and source are credited.
www.innovationinfo.org
J Cardiovas Disea Medic 2018
64
countries are related to alcohol misuse [4], and this disease 
develops in a cumulative, dose-dependent manner [5,6]. It is 
found in one-third to one-fourth of long-standing excessive 
alcohol consumers who have a mean lifetime cumulative 
ethanol dose >10 Kg ethanol/Kg body weight) [1,7] and it 
is the cause of high morbidity including arrhythmias and 
episodes of heart failure [8-10].
Excessive ethanol consumption exerts progressive, 
multifactorial damage to the myocardium inducing a 
diversity of noxious effects [3,7,11], most of which are 
synchronous and synergistic [7] and are only partially 
understood [11,12]. In the natural history of alcoholic 
CMP, these pathological mechanisms first produce diastolic 
[13,14] followed by systolic myocardium dysfunction [5], 
with progressive chamber dilatation and the development 
of structural changes (myocyte hypertrophy, necrosis and 
interstitial fibrosis), leading to myocyte apoptosis and cell 
loss, inducing the so-called alcohol-dilated CMP [1,4,7].  
One of the most relevant mechanisms of alcohol-induced 
heart damage is related to the disruption of structural 
myocardial proteins [15,16]. Alcohol decreases the synthesis 
of panoply of cardiac proteins, modifies their expression and 
function and increases its degradation [12]. Myofibrillary 
proteins are one of proteins most frequently affected in this 
process. Thus, actin and α-myosin are decreased by 40%, with 
a reduction of their mRNA transduction process in rodent 
models [16], causing a progressive decrease in sarcomere 
contraction, ventricular dysfunction and progressive cardiac 
functional damage. Alcohol-induced heart damage also 
involves other structural (troponin, ankyrin, desmosome-
related proteins), non-structural (mitochondrial, ribosomal, 
heat-shock proteins) and regulatory cardiac proteins 
(myostatin, IGF-1, FGF21, other cardiac myokines) [7,16-22]. 
This sequential process of alcohol-induced heart damage is 
relevant in the evaluation of the role of each specific protein 
[12].
Titin is a giant structural sarcomeric filament 
macroprotein which has shown to be clearly involved in 
contractile heart function [23-25]. This macroprotein is 
functionally related to passive myocardial stiffness and 
stress-sensitive signaling [26] and largely contributes to the 
elastic recoil of cardiac myocytes, a key-determinant factor 
in Frank-Starling relaxation, which is involved in diastolic 
left-ventricular filling [24,25,27]. Titin force, together with 
extracellular matrix, define passive myocardial stiffness 
[26-28]. Thus, titin plays a major role in heart disease and 
is involved in structural CMPs such as inherited dilated and 
hypertrophic CMP [29], and arrhythmogenic right ventricular 
dysplasia [30].  The potential involvement of titin in human 
ischemic heart disease [31], and the role of titin in diastolic 
heart failure al [32,33] have also been described.  In fact, the 
term “cardiac titin diseases” has been used to include the 
diverse heart diseases related to mutations, isoform variants, 
posttranslational modifications, hyperphosphorylation 
and upregulation of normal titin proteins involved in titin-
related heart damage [26]. Changes in gene expression and 
titin content (connectin) have been reported in experimental 
studies in striated muscle of chronic alcohol-fed rats [34,35]. 
The process of passive myocardial stiffness and 
stress-sensitive signaling has been described in the first 
steps of the natural history of alcoholic CMP [27,32], and 
echocardiography has shown diastolic dysfunction in one 
third of chronic asymptomatic men consuming a total 
lifetime dose of ethanol >5 kg Ethanol/kg body weight 
[14]. There is recent evidence that titin truncating variants 
represent a prevalent genetic predisposition for alcoholic 
CMP, and are also associated with a worse left ventricular 
ejection fraction in dilated CMP patients who consume 
alcohol above recommended levels [36]. However, Titin 
involvement in alcoholic CMP has been scarcely explored 
until date. Therefore, we hypothesized that heart titin 
content and function may be affected by ethanol in the 
progressive pathogenic process of chronic alcoholic CMP.
The aim of the present study was to evaluate the potential 
involvement of the myocardial structural sarcomeric 
protein titin in alcohol-induced heart damage. We used 
tissue of human myocardium from heart donors and 
compared the degree of titin myocardial expression either 
by immunohistochemical (IHC) or transcript levels methods 
in heavy long-term alcohol consumers with or without CMP 




In a prospective five-year study from January 2006 to 
December 2011, we consecutively studied hearts from 
subjects with traumatic or cerebrovascular brain death 
considered suitable as organ donors by the transplant 
team of the Hospital Clínic of Barcelona (Barcelona, Spain). 
Myocardial structural and functional data and histological 
samples were obtained from age-matched (+ 2 years) human 
organ donors prior to and after transplantation surgery, 
respectively.
Of 120 cadaveric donors under 70 years of age, 62 hearts 
were not suitable for transplantation and 4 samples were 
not properly recruited. Of these 58 latter organs, we finally 
selected: (i) 20 donors with a history of ethanol intake ≥ 
60 g/day for more than 10 years (10 without CMP and 10 
with CMP), and (ii) 10 control hearts from healthy people 
not eligible for implantation because of a lack of matched 
receptor or inadequate size. 
All cases were admitted to the Intensive Care Unit 
where ventilatory and hemodynamic parameters were 
appropriately maintained at normal values throughout 
hospitalization: systolic blood pressure >100 mmHg, 
PaO2>60 mmHg, and arterial pH within the normal range. 
None of the patients required in-hospital cardiopulmonary 
resuscitation maneuvers.
All the donors were white Caucasians of Spanish descent, 
who lived with their families in or around Barcelona, and 
none was indigent. The study protocol was approved by 
the Ethics and Research Committee of the Hospital Clínic 
of Barcelona (reference number HCB/2012/8005) and all 
the donor families provided informed consent for the use of 
www.innovationinfo.org
J Cardiovas Disea Medic 2018
65
myocardium tissue in this study. All procedures in patients 
follow the guidance provided in the Code of Conduct and Best 
Practice Guidelines for Journal editors and Code of Conduct 
for Journal Publishers (COPE), as well as the principles 
outlined in the Declaration of Helsinki. One third of these 
subjects had been included in previous studies on cardiac 
myostatin activity [19] and myocardial IGF-1 activity [20].
Clinical and Epidemiological Data
Using a structured questionnaire (“time-line follow-
back method”) [37], a detailed history of ethanol intake 
was retrospectively obtained by consultation with family 
members, as previously reported in similar studies 
[5,19,38]. The duration of ethanol intake was calculated 
in each group as the total cumulated period of recent or 
previous alcohol consumption in years. The body mass index 
(BMI) was determined as the current body weight relative 
to the square of the body height (BMI, Kg/m2). Patients were 
considered to have caloric malnutrition if the BMI was < 17 
Kg/m2. Protein malnutrition was assessed by the following 
parameters obtained at hospital admission: hemoglobin, 
lymphocyte count, total protein, retinol-binding protein, 
pre-albumin and albumin.
Symptoms of heart failure and risk factors including 
smoking history, diabetes, cerebrovascular disease, 
hypertension and a history of ischemic heart disease were 
determined by clinical chart review, and the functional 
class was determined according to the American Heart 
Association Criteria [39]. Chest X-ray with measurement of 
the cardiothoracic index, conventional electrocardiography 
(ECG) and bidimensional echocardiography was carried 
out (Hewlet Packard Sonos 2500, USA. End-diastolic and-
systolic diameter indices, the shortening fraction, left 
ventricular (LV) mass, and the ejection fraction (EF) were 
measured according to the standards of the American 
Society of Echocardiography [40]. CMP was defined as the 
presence of a left ventricular ejection fraction (LVEF) <50% 
and significant LV enlargement in addition to histologically 
evidenced structural cardiac damage. The personnel who 
performed and evaluated these tests were blinded to the 
alcoholic history of the patients.
Sample Processing and Immunohistochemistry  
Stainings: To perform myocardium histological studies, 
a distal 3 cm sample of the LV apex was surgically excised 
(total weight of 4-5 g) with the donor under cold perfusion. 
The specimen was cut into fragments, and one of these was 
processed for further transcriptional studies, and maintained 
frozen at -80ºC. The remaining fragments were snap frozen 
using liquid nitrogen until IHC study.  For the histological 
studies, the specimens were stained with hematoxylin-
eosin (H&E) and toluidine-blue in semi-thin sections. Two 
independent observers (JF-S and P-M), who were blinded 
to group assignment, evaluated the degree of myocardial 
cell and nuclear hypertrophy, myocytolysis (defined as the 
presence of myofiber disarray or cell vaquolization) and 
interstitial fibrosis as reported previously [38]. In case of 
discordance, consensus agreement was established. The 
degree of global histological involvement was graded as 
normal, mild, moderate, or severe (0/+/++/+++) according 
to previous histologically defined criteria [38,41].
Myocardial titin expression was evaluated using 
conventional IHC procedures. In these, assay titin polyclonal 
expression is observed by microscopic examination as a 
slight brown pigment in sarcomeric areas of the cardiac 
myocytes in the presence of the protein. The intensity of 
expression is directly related to sarcomeric titin content 
[42]. Semi-thin cryostat sections of 6µm was obtained from 
the donor heart samples with ultra-microtome and fixed by 
paraformaldehyde 4% PBS solution during 30 min. at pH 
7.40. After PBS washing, the sections were permeabilized 
with 0.1% Triton X-100 sodium citrate solution for 2 min 
at 4ºC and washed with serum for 20 min. Incubation with 
anti-titin horse polyclonal serum (Abcam 7034, Cambridge, 
UK) was performed at 4ºC for 18 h. 
The next day, PBS/Triton 0.1% solution was applied for 5 
min followed by incubation with secondary biotin antibody 
for 30 min at room temperature and the washing solution 
was repeated. Thereafter, the sections were incubated with 
ABC (Avidin-Biotin Complex, Vectron PK-7200, Burlingame, 
CA, USA) for 30 min at room temperature and washed again 
in PBS/Triton 0.1% solution. Revealing was performed with 
diaminobenzidine chromogen subtract for 10 min, under 
microscopic control, followed by 5 min of PBS/Triton 0.1%, 
and was then washed with distilled water and stained with 
H&E. After dehydration of the samples they were covered by 
DPX mounting solution for histological study.
Negative control slides were made in all the procedures 
using the same process without reagent incubation. Titin 
quantification was performed by two different qualified 
observers (JF-S and P-M) in at least 6 different fields 
(magnification 250x) of each sample, with at least 500 
myocytes per field, according to a previously described 
method [19]. The titin IHC index was calculated by dividing 
the total number of highly positively stained heart myocyte 
cells in the titin assay by the total number of myocytes 
evaluated and multiplying this value by 100, as described 
elsewhere [19,38]. Non-myocyte cells or myocytes located 
at the edges of the tissues or in the interstitium were not 
counted. 
Transcriptional Analysis
RNA isolation and Real-Time PCR. Total RNA was 
extracted using Tripure (Roche, Indianapolis, IN). Reverse 
transcriptase was performed in 20 μl, using random 
hexamers primers (Applied Biosystems, Foster City, CA) and 
0.5 µg RNA. PCR were conducted in duplicate for increased 
accuracy. Each 25 μl of reaction mixture contained 1 μl 
cDNA, 12.5 μl TaqMan Universal PCR Master Mix (Applied 
Biosystems), 250 nM probes and 900 nM primers from 
Assays-on-Demand Gene Expression Assay Mix or Assays-
by-Design Gene Expression Assay Mix (Applied Biosystems). 
Taqman Gene Expression Assays were used. Each sample 
was run in duplicate and the mean value was used to 
calculate the mRNA expression of the gene of interest and 
the housekeeping reference gene (18S). The amount of the 
gene of interest in each sample was normalized to that of 
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the reference control using the comparative (2-DeltaCT) 
method following the manufacturer’s instructions.  
Statistics
The data were analyzed using SPSS v22 statistical 
software. Differences among groups were seek using one-
way ANOVA test, after checking Normality distribution 
of parameters by Kolmogorov-Smirnov and Shappiro 
Wilkoxon tests. Pearson correlation coefficients between 
the variables were calculated. All the variables followed a 
normal distribution and were expressed as mean ± standard 
error of the mean (SEM). A two-tailed P value <0.05 was 
considered statistically significant with a confidence interval 
(CI) of 95%.
Results
After donor assessment, we collected a total of 30 heart 
samples. Of these, 20 were from chronic alcohol consumers 
(>10 years of lifetime consumption and >60 g of daily 
alcohol consumption). After the cardiac studies, the samples 
from chronic alcohol consumers were divided into two 
groups: one without evidence of dilated CMP (showing LVEF 
>50% and no histological signs of myocardial structural 
damage; n=10), and another with dilated CMP (presenting 
a LVEF <50% and histological signs of myocardial structural 
damage; n=10). In addition, in the same period, 10 healthy 
non-alcoholic donors with no evidence of heart disease were 
matched with the alcoholic group by age (+ 2 years) and 
gender, and were also included in the study. 
Table 1 summarizes the mean clinical and epidemiological 
data of the alcohol consumer donors with and without dilated 
CMP and controls included in the present study. Age and 
gender were similar in the three groups. Protein or caloric 
malnutrition was absent in all the control donors studied 
and was present in 2 alcohol consumers with CMP and in 
2 alcohol consumers without CMP, being BMIs comparable 
among the three groups. Twelve of the 20 chronic alcohol 
consumers (60%) had stable liver disease, with a moderate 
increase of aspartate aminotransferase (mean 62+12 IU/L) 
and gamma glutamyl transpeptidase (mean 73+15 IU/L) 
levels compared to non-alcohol consumer controls (p<0.05). 
As expected, daily alcohol intake, duration of alcohol intake 
and lifetime alcohol consumption were significantly higher 
in alcohol consumers with CMP as compared to those 
without CMP and the controls, in accordance to previous 
clinical series reports [38]. Cerebrovascular death tended 
to be more frequent in alcohol consumers than in controls. 
Forty percent of alcohol consumers without CMP and all 
the alcohol consumers with CMP presented an abnormal 
function class. The cardiothoracic index, end-systolic and 
end-diastolic LV diameters were significantly higher, and 
the LVEF was significantly lower in alcohol consumers 
with CMP compared to their counterparts without CMP 
and the controls. We observed a good correlation between 
the cardiothoracic index and the left ventricle end-diastolic 
diameter (r=0.68, p<0.01). Abnormal ECG findings (LV 
hypertrophy, extrasystoles, defects in conduction and 
repolarization) were present in 40% of alcohol consumers 
without CMP and 70% of alcohol consumers with CMP.









Age (years) 60.0 ± 13.9 51.4 ± 7.58 54.1 ± 10.77 n.s.
Gender (M/F, ratio) 6/4 6/4 6/4   n.s.
Daily alcohol intake (grams, mean ± 
SD) 0 113.0 ± 57.55 127.0 ± 60.19** <0.01
Duration of alcohol intake (years, 
mean ±SD) 0 19.1 ± 4.15 25.4 ± 4.53** <0.01
Lifetime dose of alcohol  
(Kg ethanol/Kg body weight, mean 
±SD
0 12.13 ± 4.04 15.26 ± 10.09** <0.01




























Cardiothoracic index (mean ± SD) 0.49 ± 0.028 0.5 ± 0.017 0.57 ± 0.069* <0.05
End-systolic diameter 
(mm/m2, mean ± SD) 17.2 ± 1.7 19.7 ± 3.5 28.5 ± 6.5** <0.01
End-diastolic diameter 
(mm/m2 , mean ± SD) 28.3 ± 1.6 29.9 ± 3.4 35.1 ± 6.2** <0.01
Left ventricular ejection fraction (%, 
mean ± SD) 60 ± 3 55 ± 5 38 ± 7** <0.01
Electrocardiogram 
(abnormal cases, n%) 2 4 7 <0.05***
*p<0.05 compared to alcohol consumers without CMP and controls, **p<0.01 compared to alcohol consumers without CMP and controls, ***p<0.05 compared to 
controls. ANOVA test, after checking Normality distribution of parameters by Kolmogorov-Smirnov and Shappiro Wilkoxon tests. M/F: male/female, NYHA: New 
York Heart Association, SD: Standard Deviation
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Table 2 shows the degree of histological damage 
according to the semi-quantitative score (absent/low/
moderate/severe) applied in the histological myocardial 
study. As expected, alcohol consumers with CMP presented 
a greater degree of histological damage (myocyte 
hypertrophy, necrosis and interstitial fibrosis) compared 
to their counterparts without CMP and to the non-alcohol 
consumer controls (p<0.05).
Negative controls for IHQ were only stained with 
hematoxylin (Figure 1A). After processing and microscopic 
evaluation of all the samples for titin IHC expression, a dark 
brown color in sarcomere areas showed clear positivity 
where the titin specific antibody was used (Figure 1B). The 
inter-myocyte variability in titin expression was of note 
(Figure 1B) in that some cardiac myocytes clearly expressed 
titin while others showed low titin expression, where the 
primary antibody was not captured by sarcomere.
Table 2 and Figures 1 and 2 show the cardiac titin IHC 
expression. First, we compared the percentage of titin 
IHC expression in healthy donors versus the two alcohol 
consumer groups, and we found that alcohol consumer 


































































CMP: Cardiomyopathy, SD: Standard Deviation, NS: Nonsignificant, 
*Compared to alcohol consumer donors without cardiomyopathy and 
controls. ANOVA test, after checking Normality distribution of parameters by 
Kolmogorov-Smirnov and Shappiro Wilkoxon tests.
Table 2: Degree of histological damage and immunohistochemical (IHC) titin 














Figure 1:  Titin immunohistochemical cardiac studies in control non-alcohol consumer donors (n=10) and chronic alcohol 
consumer donors (n=20). Figure 1A: Negative heart controls only stained with hematoxylin. Figure 1B: Positive heart control 
with titin-specific antibody staining showing clear slight positivity by a dark brown color in sarcomere areas (arrows). Figure 1C: 
Alcohol consumer donor without CMP showing positive titin expression in a high percentage of myocytes (arrow), similar to the 
pattern from a non-alcohol consumer control. Figure 1D: Alcohol consumer donor with CMP showing a significant decrease in the 
immunohistochemical titin expression. Magnification x 400.  Scale bar: 100μm.
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p=0.003). Similarly, titin IHC expression was significantly 
lower in alcohol consumer donors with CMP compared to 
healthy controls non-alcohol consumers (62.31+4.18% vs. 
82.58+3.36%, p=0.0009).
Figures 1C and 1D shows the different titin IHC expression 
according to the presence or absence of CMP. Thus, chronic 
alcohol consumer donors without CMP (Figure 1C) showed 
positive titin expression in a high percentage of myocytes 
(similar to healthy controls non-alcohol consumers) 
compared to chronic alcohol consumer donors with CMP 
(Figure 1D) who had a clear and significant decrease in IHC 
titin expression.
Figure 3 shows the relationship between the different 
groups of donors evaluated and the percentage of myocardial 
titin expression (% of higher titin IHC-positive cells).
To confirm these findings, Titin levels were parallelly 
evaluated through transcriptional assays and found similar 
patterns than those evaluated through IHQ, in all studied 
groups (Figure 3). 
Discussion
The objective of the present study was to assess the 
effect of chronic alcohol consumption and the presence 
of CMP on titin expression in different groups of human 
heart donors. To that aim, we performed an IHC staining 
and transcriptional analysis in myocardial tissue from 
healthy control human donors and donors with high-dose 
chronic alcohol consumption to detect the expression of the 
sarcomeric titin protein in cardiac myocytes.
As described previously, titin was clearly expressed with 
a characteristic brown stain [42,43] in the sarcomeric area 
of the majority of cardiac myocytes (83%) in healthy non-
alcohol consumer control donors. On comparing healthy 
non-alcohol consumer controls with all the chronic alcohol 
consumers, we found the cardiac expression of titin to be 
significantly lower in donors who had consumed significant 
high doses of alcohol, demonstrating a direct effect of 
chronic alcohol consumption on decreasing titin IHC cardiac 
expression. In addition, when we evaluated the role of 
dilated CMP in alcohol consumer donors, we also observed 
that IHC titin decrease was significant in myocardial alcohol 
consumers with CMP compared to both those without CMP 
and non-alcohol consumer controls. These different patterns 
of Titin expression, despite non-significant, were confirmed 
by alternative techniques as transcriptional assays were we 
found a tendency to decrease Titin 18/SR mRNA transcription 
levels in those chronic alcohol consumers affected or not 
of CMP in comparison to non-alcoholic controls. This fact 
suggests that the decrease in cardiac myocyte Titin mRNA 
transcription content could be mainly related to chronic 
alcohol effect than to the presence of CMP and that protein 
expression is more relevant than transcript.
Furthermore, the negative effect of alcohol on myocyte 
titin IHC expression in the presence of CMP is in concordance 
with what happens to other sarcomeric structural proteins 
such as actin and myosin that are also affected by alcohol 
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Figure 3: Titin immunohistochemical expression in alcohol consumer donors 
with (n=10) and without cardiomyopathy (CMP) (n=10) and non-alcohol 
consumer controls (n=10). Results expressed in % of positive cells (mean + 
SEM); ANOVA test, after checking Normality distribution of parameters by 
Kolmogorov-Smirnov and Shappiro Wilkoxon tests.









































Figure 2: Titin transcriptional expression in alcohol consumer donors 
with (n=10) and without cardiomyopathy (CMP) (n=10) and non-alcohol 
consumer controls (n=10). Results expressed in Titin RNA/18SrRNA 
(mean + SEM); ANOVA test, after checking Normality distribution of 
parameters by Kolmogorov-Smirnov and Shappiro Wilkoxon tests.
expression (healthy donors 82.58%+3.36 vs. all chronic 
alcohol consumer donors 71.29+3.16, p=0.04).
In order to assess if the presence of CMP was relevant 
for cardiac titin IHC activity, we divided the group of alcohol 
consumer donors according to the presence or absence of 
CMP and compared these with the control donors. Table 
2 shows the means and 95% CI of these three groups. We 
observed a significant decrease in IHC titin activity in 
chronic alcohol consumers with CMP compared to their 
counterparts without CMP (62.31+4.18% vs. 80.27+2.62%, 
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process [45,46]. In the case of titin, since it is a sarcomeric 
protein functionally related to the cardiac relaxation 
process [26,47], the findings of the present study provide 
additional evidence of the damaging effect of chronic ethanol 
consumption which induces LV diastolic dysfunction in one 
third of chronic alcohol misusers [13,14].
However, this decreased titin myocyte expression is 
not specific of alcohol-induced CMP since sarcomeric titin 
content may also be decreased by many other causes of 
heart damage such as inherited hypertrophic and dilated 
CMP [29], ischemic cardiopathy [31] idiopathic dilated CMP 
[28], arterial hypertension [42,48] and arrhythmogenic 
right ventricular dysplasia [30]. In fact, the term “cardiac 
titin diseases” has been proposed and includes all cardiac 
diseases involved in titin dysfunction [26].
Similar to that happens at a clinical level, different 
experimental studies in rats have evaluated whether 
chronic alcohol consumption disrupts myocardial 
contractile proteins [12,15,44]. Specifically, alcohol 
decreases the α-actin isoform and the myosin heavy chain 
by 40% but increases the β-actin isoform [16]. Changes 
in gene expression and isoform composition but not in 
total titin content in cardiac muscle of chronically ethanol-
fed rats have been described, suggesting that these 
changes are involved in the development of pathologic 
processes [35].  In accordance to what happens with these 
myofibrillary proteins, several non-structural myocardial 
proteins involving mitochondrial function, membrane-
related proteins, glycolytic enzymes, transduction-signal 
sarcoplasmic proteins, genetic transduction-related proteins 
and antioxidant mechanisms are affected by chronic alcohol 
consumption [12,16]. In addition, a clear decrease in heat-
shock proteins also develops, producing a loss in myocardial 
protective mechanisms [18]. With respect to titin, in 
experimental studies in rats, titin cardiac isoform expression 
was decreased in LV with increased hypertrophy [42] or in 
the presence of pulmonary hypertension [49]. A reduction 
in titin may produce sarcomeric insufficiency and contribute 
to the development of dilated CMP [28]. Thus, the multiple 
effects induced by ethanol itself in cardiac myocytes [7] are 
further increased when structural proteins such as titin are 
altered.
With respect to study limitations, since this study was 
performed in human heart donors, the sample size was 
limited due to the difficulty in obtaining this type of human 
specimen, and this may minimize some group comparisons 
with difficult statistical findings, in case of transcriptional 
assays. No other changes in posttranslational modifications 
of titin, phosphorylation or titin genotypes were analyzed in 
this study. Epitopes of Titin may affect the binding specific 
of the anti-titin antibodies used in this study [36]. Therefore, 
changes in titin expression are merely associated with 
alcoholic CMP and do not demonstrate a causal relationship 
between titin and alcoholic CMP. Similarly, evaluation 
of diastolic function was not included in the cardiac 
assessment of the donors. Lastly, alcohol consumption was 
retrospectively evaluated by consultation with family and 
relatives of heart donors.
Despite these inconveniences and according to the results 
of the present study, we can conclude that chronic excessive 
alcohol consumption significantly decreases titin myocardial 
expression, with this alcohol-induced effect being higher 
when structural cardiac damage and remodeling are present. 
Since titin is a structural protein related to LV distensibility, 
this decrease in titin expression may justify the previously 
described LV diastolic dysfunction reported in one third 
of chronic alcohol users in the subclinical phase of CMP 
[13,14]. This fact may also be related to the development of 
the so-called heart failure with preserved ejection fraction 
[33,48,49].
Titin cardiac expression may be used as an additional 
marker of alcohol-induced heart damage which appears in 
first steps of subclinical alcohol-dilated CMP. Indeed, cardiac 
expression of titin significantly decreases in the process of 
cardiac remodeling and dilated CMP.  Strategies to preserve 
myocardial titin activity as well as other cardiac proteins, 
avoid protein malnutrition, lack of physical exercise, and 
oxidative damage, and stabilize liver or other alcohol-
related systemic diseases [50] may contribute to preventing 
the progressive development of cardiac dysfunction and 
structural damage in alcoholic CMP.
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